Trial
NCT06340581
A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
AstraZeneca
Collaborators
Parexel
Condition
Healthy
Intervention
Treatment A: BGF MDI HFA
Why stopped
Study no longer required.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-08-15